Share to WeChat
Open WeChat, click “Discover” at the bottom, |
First Financial 2022-06-06 15:46:00
Editor in charge: Hao Yunying
Xin Litai, a pharmaceutical stock with a total market value of nearly 30 billion yuan, announced that the company and Shenzhen Kexing signed an agreement on CDMO technical services and entrusted production of anti-new coronavirus small molecule oral drugs. Shenzhen Kexing entrusted Xinlitai and Huizhou Xinlitai to carry out SHEN26 project drug CDMO services and commissioned processing of APIs and preparations. SHEN26 is an antiviral drug owned by Shenzhen Kexing Pharmaceutical Co., Ltd. for the treatment of COVID-19 and other viral infections. So far, all pharmaceutical and non-clinical research work has been completed.
30 billion pharmaceutical stocks and Kexing signed a new crown oral drug entrusted production agreement, the stock price was once halved | News Focus
Xin Litai, a pharmaceutical stock with a total market value of nearly 30 billion yuan, announced that the company and Shenzhen Kexing signed an agreement on CDMO technical services and entrusted production of anti-new coronavirus small molecule oral drugs. Shenzhen Kexing entrusted Xinlitai and Huizhou Xinlitai to carry out SHEN26 project drug CDMO services and commissioned processing of APIs and preparations. SHEN26 is an antiviral drug owned by Shenzhen Kexing Pharmaceutical Co., Ltd. for the treatment of COVID-19 and other viral infections. So far, all pharmaceutical and non-clinical research work has been completed.